VOLUME - 15, ISSUE - 09, SEPTEMBER - 2026 • PRINT ISSN No. 2277 - 8160 • DOI : 10.36106/gjra

Original Research Paper

Cardiovascular Surgery

OPTOGENETIC TERMINATION OF RE-ENTRANT ARRHYTHMIAS: A COMPREHENSIVE ANALYSIS

Prof Dr Pradeep Kumar Radhakrishnan	MS, MCh CTVS AIIMS Delhi, Post-doctoral fellow CTVS SCTIMST, Postdoctoral Fellow in ECMO, FACC, FIACS, CPDH- IISc, Global MBA Lond, Director Biomexia, Prof CTVS and HOD CTVS YANS Medical Institute
Dr Gayathri Ananyajyothi Ambat	MBBS, Junior Resident, YANS Medical Institute, Kerala India
Dr Nihaz Nazer	MS MCh, Director YANS Medical Institute
Prof Y A Nazer	MS, MCh AIIMS, Chairman YANS Medical Institute Trivandrum Kerala India

KEYWORDS : Cardiac Optogenetics, Re-Entrant Tachyarrhythmias, Biological Cardioversion, Channel Rhodopsin, Excitable Gap, Scarless Arrhythmia Control

INTRODUCTION

Malignant cardiac tachyarrhythmias, such as ventricular tachycardia (VT) and atrial fibrillation (AF), represent leading causes of global mortality and morbidity. These life-threatening conditions are predominantly sustained by a re-entry mechanism, where a circular, self-sustaining electrical wave continuously reactivates cardiac tissue. [1, 2]

Conventional clinical strategies to manage re-entry rely on anti-arrhythmic drugs, high-voltage electrical shocks via implantable cardioverter-defibrillators (ICDs), or catheter-based thermal ablation. While electrical shocks save lives, they inflict severe pain, induce myocardial tissue damage, and trigger psychological trauma. Concurrently, traditional catheter ablation permanently destroys cardiac tissue, leaving behind irreversible scar tissue that can paradoxically act as a substrate for future arrhythmias. [1, 2]

To overcome these structural limitations, cardiac optogenetics has emerged as a ground-breaking paradigm. By integrating genetic engineering and optical technology, this biological approach offers a painless, non-destructive, and spatially precise method to terminate re-entrant circuits without generating permanent scar tissue. [1]

In-Depth Analysis

1. Concept of Optogenetic Arrhythmia Control

The foundational concept of cardiac optogenetics involves rendering normally light-insensitive cardiomyocytes sensitive to specific wavelengths of light. This is achieved by the heterologous expression of microbial derived light-sensitive proteins called opsins within the sarcolemma of heart cells. When these opsins absorb photons, they undergo conformational changes that permit the selective influx or efflux of ions. By choosing specific opsins, researchers can either selectively depolarize or hyperpolarize cardiac tissue on demand. [1, 2, 3, 4]

In the context of re-entrant arrhythmias, optogenetics targets the core biophysical properties of the circulating electrical wave front. A re-entrant circuit requires two components to persist: a pathway of excitable tissue (the excitable gap) ahead of the wave front, and a region of slow conduction. Optogenetic termination breaks this loop via three primary biophysical mechanisms: [1, 2]

- Conduction Block by Continuous Depolarization: Delivering a continuous pulse of light activates depolarizing opsins (e.g., Channelrhodopsin-2), holding the tissue in an absolute refractory state. This creates a temporary, fully reversible physical barrier that stops the advancing wave front. [1]
- Filling the Excitable Gap: Brief, strategically timed light pulses can trigger action potentials within the excitable gap immediately ahead of the re-entrant rotor. This forces a head-on wave collision that extinguishes the arrhythmia. [1]
- Direct Hyperpolarization: Activating anion-conducting or proton-pumping opsins drives the membrane potential down, suppressing excitability instantly to extinguish the circuit. [1, 2]

2. METHODOLOGY

Implementing optogenetic termination involves a sophisticated, multi-step pipeline spanning gene therapy, molecular biology, and optoelectronics:

[Vector Engineering]⇒[Gene Delivery]⇒[Opsin Expression]⇒[Optical Interfacing]
(AAV9 / ReaChR) (Systemic/Local) (Cardiomyocytes) (LEDs / Feedbacks)

- Vector Design and Opsin Selection: The genetic construct typically pairs a cardiotropic viral vehicle, such as Adeno-Associated Virus Serotype 9 (AAV9), with a cell-specific promoter like Cardiac Troponin T (cTnT). This restricts expression strictly to cardiomyocytes. Classic opsins like Channelrhodopsin-2 (ChR2) require blue light, which suffers from poor tissue penetration. Consequently, modern translational protocols favour red-shifted variants like ReaChR or Chrimson, which safely penetrate deep into thick ventricular walls.
- Gene Delivery: The viral vector is introduced either via systemic intravenous injection or via direct, localized intracoronary infusion into the myocardium.
- Optical Interfacing and Delivery: Light is supplied via biocompatible, flexible epicardial Micro-LED arrays or bioresorbable optical fibres integrated with an active sensing device.
- Control Algorithms: Closed-loop systems track the heart's real-time electrical activity to dynamically adjust light pulses. Techniques like Optically Resonant Feedback Pacing (ORFP) use real-time tracking to modulate tissue excitability at sub-threshold light levels, causing the re-entrant spiral wave to drift and extinguish itself with minimal energy expenditure. [1, 2, 3, 4]

3. Current Translational Status

While cardiac optogenetics has achieved remarkable success in proof-of-concept setups, it remains in the pre-clinical translational phase.

- In Vitro and In Silico Success: Highly accurate computational simulations utilizing patient-derived MRI scans demonstrate that targeted illumination of the critical isthmus in fibrotic human atria achieves a 100% termination rate.
- In Vivo Animal Models: Successful shock-free biological cardioversion of induced ventricular and atrial tachyarrhythmias has been consistently executed in small animal models, including mice and adult Wistar rats.
- Human Tissue Validation: Researchers have successfully transmitted light pulses through excised human left atrial tissue from cardiac surgery patients, validating that human atrial wall thickness is not an absolute barrier to modern optoelectronic components.
- Remaining Timeline: Transitioning to human clinical trials is projected to take 7 to 10 years, contingent on resolving long-term gene safety profiles, optimizing red-shifted opsin expression in large mammals, and engineering durable, bio-compatible intracardiac light delivery devices. [1, 2, 3, 4, 5, 6]

4. Clinical Indications

Once translated, optogenetic termination will target specific patient populations plagued by recurrent re-entrant pathways:

- Recurrent, Refractory Ventricular Tachycardia: Patients with ischemic cardiomyopathy or old myocardial infarctions who suffer from recurrent VT episodes and experience frequent, painful ICD shocks. [1, 2]
- Persistent Atrial Fibrillation and Flutter: Patients with extensive atrial fibrosis where traditional pulmonary vein isolation fails, or those requiring repeated electrical cardioversions. [1, 2]
- Congenital Substrates (e.g., Wolff-Parkinson-White Syndrome): Pediatric or young adult populations with accessory pathways where lifelong drug therapy or destructive ablation carries higher risks.

5. Complications and Limitations

Despite its immense therapeutic promise, several biological and technical risks must be mitigated:

- Immunogenicity: The long-term expression of microbial opsin proteins can trigger a robust cell-mediated immune response, leading to chronic myocarditis or the destruction of light-sensitive cardiomyocytes.
- Insertional Mutagenesis: Although AAV vectors generally remain episomal, non-targeted genomic integration could disrupt critical host genes, potentially inducing oncogenesis or cardiac dysfunction.
- Pro-Arrhythmic Risks: Incomplete or sub-transmural illumination can create areas of heterogeneous refractoriness. This can inadvertently induce new, more complex re-entrant circuits or fragment a stable tachycardia into chaotic fibrillation.
- Photothermal Tissue Damage: Delivering high-intensity light continuously to achieve a conduction block can generate local heat, leading to inadvertent thermal injury of the myocardium.
- Opsin Degradation and Gene Silencing: Over time, epigenetic silencing or natural protein turnover can result in a loss of transgene expression, requiring hazardous repeat vector administrations. [1, 2, 3]

6. Discussion: Innovative Future Methods vs. Optogenetics

To eliminate the structural risks of traditional thermal ablation, several innovative, non-thermal arrhythmia control strategies have entered development.

Methodology	Mechanism	Scar Tissue Avoidance	Spatial/Temporal Precision	Reversibility
Pulsed Field Ablation (PFA)	Ultra-rapid electrical fields cause irreversible electroporation of cell membranes.	**Partial.** Avoids collateral matrix damage but still relies on cell death.	High spatial, low temporal.	**No.** Causes permanent tissue death.
Stereotactic Arrhythmia Radioablation (STAR)	Focused, high-dose ionizing radiation induces cellular fibrosis.	**No.** Intentionally creates a dense fibrotic scar to block conduction.	Moderate spatial, delayed temporal.	**No.** Permanent structural alteration.
Gene-Based Ion Channel Modulation	Overexpression of native ion channels (e.g., Kir2.1) alters baseline	**Yes.** Completely biological modification.	Low spatial, zero temporal control.	**No.** Permanently alters baseline physiology.

Why Optogenetics is Superior

Optogenetics stands superior to all alternative next-generation modalities because it is the only truly functional, fully reversible, non-destructive biological intervention. [1]

Unlike PFA and STAR, which require killing cardiac cells to stop an arrhythmia, optogenetics leaves the myocardium structurally completely intact. It works by applying a temporary, highly localized functional block. When the light shuts off, the tissue immediately regains its natural electrical properties. [1]

Furthermore, while constitutive gene therapy permanently alters the heart's baseline electrophysiology (potentially causing bradycardia or heart blocks during normal sinus rhythm), optogenetics remains completely silent. The engineered channels sit completely dormant, activating only during an arrhythmic emergency when the light interface switches on. This combination of millisecond-level temporal precision and absolute structural preservation makes optogenetics the ultimate paradigm for cardiac rhythm management. [1, 2, 3, 4]

Summary of Future Applications

- Painless Autonomous Bio-ICDs: The development of implantable, low-energy optical defibrillators that silently terminate malignant ventricular fibrillation without delivering agonizing high-voltage shocks.
- All-Optical Closed-Loop Electrotherapeutics: Integrated medical devices that combine genetically encoded voltage indicators (GEVIs) to sense an arrhythmia and optogenetic actuators to terminate it instantly.
- Dynamic, Multi-Site Biological Pacing: Light-driven pacing arrays capable of shifting pacing sites in real time, optimizing ventricular synchronization without lead-induced mechanical fatigue.
- Patient-Specific Virtual Electrophysiology: Pairing patient-derived computational heart models with targeted light therapy to run preventative simulations, identifying an individual's unique arrhythmic risks before deploying an implant. [1, 2, 3]
- To bridge the translation gap between small-animal models and human clinical application, contemporary cardiac optogenetics relies heavily on advanced molecular engineering, patient-specific computational frameworks, and rigorous comparative benchmarking against modalities like Pulsed Field Ablation (PFA). To achieve the necessary deep transmural ventricular illumination without inducing photothermal injury, researchers have engineered optimized red-shifted opsins, most notably ChrimsonR (with mutations like K176R) and ReaChR. These variants exhibit shifted activation spectra toward red and near-infrared wavelengths (exceeding 600 nm), allowing photons to penetrate thick, highly scattering mammalian myo-cardium while boasting faster deactivation kinetics to follow rapid re-entrant rates without desensitisation. Concurrently, translation is guided by state-of-the-art in silico modelling frameworks; these combine patient-specific late gadolinium-enhancement MRI scans with multi-scale biophysical flow-network simulations (such as the *Monodomain* or *Bidomain* models) to map precise fibre orientation and fibrotic remodelling. These virtual

simulations accurately predict the minimum photon density and the exact spatial coordinates of the critical isthmus required for termination before any physical intervention. Furthermore, recent large-animal comparative trials indicate that while PFA successfully avoids the collateral phrenic nerve and oesophageal damage associated with thermal ablation, it still leaves a permanent anatomical scar by forcing cell death. Optogenetics, by contrast, matches the tissue-selectivity of PFA but achieves complete biological cardioversion by steering membrane potential dynamically without altering structural integrity or causing micro-lesions, solidifying its place as the premier scarless electro-therapeutic strategy.

Opsin Biophysical Profiles & Comparative Metrics

Selecting the correct molecular actuator requires balancing tissue penetration against channel kinetics. Below is a direct comparison of the key biophysical parameters governing the primary microbial opsins utilized in cardiac electrophysiology

Opsin Variant	Peak Excitation Wavelength (λ_{max})	Deactivation Time Constant (τ_{off})	Minimum Light Intensity Threshold	Primary Biophysical Advantage / Constraint
Channelrhodopsin-2 (ChR2)	~470 nm (Blue)	~10–12 ms	~0.5–1.0 mW/mm^2	**High kinetics, poor penetration.** Excellent for surface pacing; highly scattered by hemoglobin, restricting transmural ventricular use.
ReaChR (Red-activated ChR)	~590–630 nm (Red)	~15–20 ms	~0.1–0.4 mW/mm^2	**Deep penetration, moderate kinetics.** Optimized for thick ventricular walls; reduces photothermal risk due to low intensity requirements.
ChrimsonR (K176R mutant)	~595–660 nm (Far-red)	~15–25 ms	~0.2–0.5 mW/mm^2	**Maximum tissue penetration.** Fastest off-kinetics among red-shifted opsins, allowing it to easily track high-frequency tachyarrhythmias (>5 Hz).

Gene Therapy Safety Protocol

Phase 1: Pre-Screening and Patient Exclusion

- Neutralising Antibody (NAb) Screening: Evaluate patients via enzyme-linked immunosorbent assays (ELISA) to quantify pre-existing anti-AAV9 antibodies. High NAb titers (>1:5) necessitate exclusion or plasmapheresis to prevent immediate humoral immune clearance.
- Genomic Baseline Profiling: Map baseline somatic mutations to accurately monitor potential clonal expansions post-treatment.

Phase 2: Regulated Delivery and Vector Containment

- Cardiomyocyte-Restricted Expression: Utilize the minimal human Cardiac Troponin T (cTnT) or α-Myosin Heavy Chain (α-MHC) promoter within the AAV9 vector to prevent off-target expression in hepatic, splenic, or skeletal muscle tissues.
- Intracoronary Micro-Dosing: Deploy vector delivery through an over-the-wire balloon catheter during transient ischemic isolation. This maximizes myocardial uptake while minimizing systemic spill over into the systemic circulation.

Phase 3: Immediate Post-Operative Immunomodulation

- Prophylactic Immunosuppression: Administer a tapered course of oral corticosteroids (e.g., Prednisone at 1 mg/kg/day) starting 24 hours' pre-injection and continuing for 4–6 weeks to suppress the initial T-cell-mediated response against the AAV9 capsid.
- Biomarker Surveillance: Measure serum Cardiac Troponin I (cTnI) and High-Sensitivity C-Reactive Protein (hs-CRP) weekly for the first 3 months to detect sub-clinical myocardial inflammation or cellular destruction.

Phase 4: Long-Term Genomic and Physiological Surveillance

- Liquid Biopsy for episomal stability: Conduct droplet digital PCR (ddPCR) on peripheral blood samples to monitor systemic clearance of circulating viral genomes.
- Epigenetic and Integration Profiling: In the event of post-mortem analysis or necessary endomyocardial biopsy, perform Inverted Terminal Repeat (ITR) sequencing to verify that the vector remains strictly episomal and has not integrated near known proto-oncogenes.

Regulatory Pathway Requirements (FDA Combination Products)

Because cardiac optogenetics pairs a genetically encoded biologic with an optoelectronic hardware interface, it falls under the jurisdiction of the FDA Intercenter Combination Products Program. It requires joint review by the Center for Biologics Evaluation and Research (CBER) and the Center for Devices and Radiological Health (CDRH).

1. Primary Mode of Action (PMOA) Determination

- The FDA assigns the primary review mandate based on the product's core therapeutic action. In this framework, the gene therapy vector (biologic) is designated as the PMOA because the light device has no therapeutic effect without the expression of the opsin. Thus, CBER acts as the lead center, reviewing the strategy under a Biologics License Application (BLA), while CDRH provides consult technical reviews for the hardware component under a Premarket Approval (PMA) track.

2. Investigational Device Exemption (IDE) & Investigational New Drug (IND) Applications

- To initiate clinical trials, developers must concurrently secure an approved IND application for the AAV9-opsin construct and an IDE application for the implantable Micro-LED cardiac array. Pre-clinical packages must prove structural device integrity over 10^9 flexural cycles and rule out chronic toxicity from structural bio-materials.

3. Phased Clinical Trial Expectations

[Phase I: Safety & Tolerability] (Small Cohort; N=10-20) ⇒ [Phase II: Dose-Finding & Efficacy] (Dose Escalation; N=50-100) ⇒ [Phase III: Multi-Center Trial] (Randomised; N=300+)

Phase I (Safety and Tolerability): Conducted in a small cohort (N = 10–20) of patients with end-stage, refractory VT who are already scheduled for mechanical heart support or transplantation. The primary endpoint is the absence of vector-induced anaphylaxis, severe myocarditis, or device migration over a 6-month window.

- Phase II (Dose-Finding and Proof-of-Concept): Evaluates vector dose escalation (ranging from 1×10^{12} to 1×10^{14} vector genomes/kg) alongside light intensity titration (0.1–2.0 mW/mm^2) in 50–100 patients. The focus is establishing the minimal effective energy threshold for successful biological cardioversion during induced VT in a controlled electrophysiology lab.
- Phase III (Pivotal Efficacy Trials): A multi-center, randomized, controlled trial (N > 300) comparing the optogenetic bio-ICD directly against standard high-voltage thermal ICDs. The primary efficacy endpoint is the successful termination rate of spontaneous ventricular tachyarrhythmias, while the primary safety endpoint measures the reduction in shock-induced myocardial injury and related patient psychological trauma.

REFERENCES

1. Bruegmann T, Malan D, Hesse M, et al. Optogenetic control of heart muscle in vitro and in vivo. *Nature Methods*. 2010;7(11):897–900. doi: 10.1038/nmeth.1512.
2. Nyns ECA, Kip A, Bart CI, et al. Optogenetic termination of ventricular arrhythmias in the whole heart: towards biological cardiac rhythm management. *European Heart Journal*. 2017;38(27):2132–2136. doi: 10.1093/eurheartj/ehw574.

3. Biktashev VN, Holden AV. Design principles of a low voltage cardiac defibrillator based on the effect of feedback resonant drift. *Journal of Theoretical Biology*. 1994;169(2):101–112. doi: 10.1006/jtbi.1994.1132.
4. Boyle PM, Murphy MJ, Karathanos TV, Zahid S, Blake RC III, Trayanova NA. Termination of re-entrant atrial tachycardia via optogenetic stimulation with optimized spatial targeting: insights from computational models. *The Journal of Physiology*. 2018;596(2):181–196. doi: 10.1113/JP275264.
5. Crocini C, Ferrantini C, Coppini R, et al. Optogenetics design of mechanistically-based stimulation patterns for cardiac defibrillation. *Scientific Reports*. 2016; 6:35628. doi: 10.1038/srep35628.
6. Watanabe M, Feola I, Majumder R, et al. Optogenetic manipulation of anatomical re-entry by light-guided generation of a reversible local conduction block. *Cardiovascular Research*. 2017;113(3):354–366. doi: 10.1093/cvr/cvx003.
7. Ochs AR, Karathanos TV, Trayanova NA, Boyle PM. Optogenetic stimulation using anion channelrhodopsin (GtACR1) facilitates termination of re-entrant arrhythmias with low light energy requirements: a computational study. *Frontiers in Physiology*. 2021; 12:718622. doi: 10.3389/fphys.2021.718622.
8. Hussaini S, Mamyraiym Kyzy A, Schröder-Schetelig J, et al. Efficient termination of cardiac arrhythmias using optogenetic resonant feedback pacing. *Chaos*. 2024;34(3):031103. doi: 10.1063/5.0191519.
9. Entcheva E, Kay MW. Cardiac optogenetics: a decade of enlightenment. *Nature Reviews Cardiology*. 2021;18(5):349–367. doi: 10.1038/s41569-020-00478-0.
10. Majumder R, Feola I, Teplenin AS, de Vries AAF, Panfilov AV, Pijnappels DA. Optogenetics enables real-time spatiotemporal control over spiral wave dynamics in an excitable cardiac system. *eLife*. 2018;7: e41076. doi: 10.7554/eLife.41076.
11. Funken M, Malan D, Sasse P, Bruegmann T. Optogenetic hyperpolarization of cardiomyocytes terminates ventricular arrhythmia. *Frontiers in Physiology*. 2019; 10:498. doi: 10.3389/fphys.2019.00498.
12. Feola I, Volkers L, Majumder R, et al. Localized optogenetic targeting of rotors in atrial cardiomyocyte monolayers. *Circulation: Arrhythmia and Electrophysiology*. 2017;10. doi: 10.1161/CIRCEP.117.005591.